#SFHS2613701AFrance Adds and Extends Coverage for Jakavi in Graft-Versus-Host Disease
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds Jakavi oral solution and extends coverage for Jakavi tablets on the list of medicines approved for use by hospitals, public institutions, and other public services in France. Coverage applies to ruxolitinib treatment for certain adult and pediatric patients with acute or chronic graft-versus-host disease who have not responded well enough to corticosteroids or other systemic treatments. Hospitals, public purchasers, clinicians, and Novartis are the main parties affected.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Jakavi 5 mg/ml oral solution to the list of medicines approved for public-sector use
- Extends coverage for Jakavi 5 mg tablets to specified graft-versus-host disease indications
- Limits reimbursable use to patients who have not responded adequately to corticosteroids or other systemic treatments
Obligations
What this law requires
Hospitals, public institutions, and other public services may use and seek coverage for JAKAVI 5 mg/ml ruxolitinib oral solution only for the listed reimbursable indications: treatment of acute graft-versus-host disease in adults and pediatric patients aged 28 days or older with inadequate response to corticosteroids or other systemic treatments, and treatment of chronic graft-versus-host disease in adults and pediatric patients aged 6 months or older with inadequate response to corticosteroids or other systemic treatments.
Coverage for JAKAVI 5 mg ruxolitinib tablets is extended only to the specified graft-versus-host disease indications: acute disease in adults and pediatric patients aged 28 days or older with inadequate response to corticosteroids or other systemic treatments, and chronic disease in adults and pediatric patients aged 6 months or older with inadequate response to corticosteroids or other systemic treatments.